Cargando…

Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort

We examined 2-year longitudinal change in clinical features and biomarkers in LRRK2 non-manifesting carriers (NMCs) versus healthy controls (HCs) enrolled in the Parkinson’s Progression Markers Initiative (PPMI). We analyzed 2-year longitudinal data from 176 LRRK2 G2019S NMCs and 185 HCs. All partic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simuni, Tanya, Merchant, Kalpana, Brumm, Michael C., Cho, Hyunkeun, Caspell-Garcia, Chelsea, Coffey, Christopher S., Chahine, Lana M., Alcalay, Roy N., Nudelman, Kelly, Foroud, Tatiana, Mollenhauer, Brit, Siderowf, Andrew, Tanner, Caroline, Iwaki, Hirotaka, Sherer, Todd, Marek, Kenneth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588016/ https://www.ncbi.nlm.nih.gov/pubmed/36273008 http://dx.doi.org/10.1038/s41531-022-00404-w

Ejemplares similares

LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts
por: Merchant, Kalpana M., et al.
Publicado: (2023)

Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort
por: Simuni, Tanya, et al.
Publicado: (2018)

The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort
por: Marek, Kenneth, et al.
Publicado: (2018)

Proposal for a Biologic Staging System of Parkinson’s Disease
por: Chahine, Lana M., et al.
Publicado: (2023)

Impact of the Dopamine System on Long‐Term Cognitive Impairment in Parkinson Disease: An Exploratory Study
por: Weintraub, Daniel, et al.
Publicado: (2023)

Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression
por: Brumm, Michael C., et al.
Publicado: (2023)

Dopamine transporter imaging predicts clinically‐defined α‐synucleinopathy in REM sleep behavior disorder
por: Chahine, Lana M., et al.
Publicado: (2020)

Predicting Progression in Parkinson’s Disease Using Baseline and 1-Year Change Measures
por: Chahine, Lana M., et al.
Publicado: (2019)

Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease
por: Irwin, David J., et al.
Publicado: (2020)

Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort
por: Simuni, Tanya, et al.
Publicado: (2018)

Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease
por: Weintraub, Daniel, et al.
Publicado: (2020)

Longitudinal Measurements of Glucocerebrosidase activity in Parkinson’s patients
por: Alcalay, Roy N., et al.
Publicado: (2020)

Longitudinal Analyses of Cerebrospinal Fluid α-Synuclein in Prodromal and Early Parkinson’s Disease
por: Mollenhauer, Brit, et al.
Publicado: (2019)

Cognition among individuals along a spectrum of increased risk for Parkinson’s disease
por: Chahine, Lana M., et al.
Publicado: (2018)

Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for α-Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4)
por: Chahine, Lana M., et al.
Publicado: (2018)

Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older
por: Brumm, Michael C., et al.
Publicado: (2023)

In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease
por: Chahine, Lana M., et al.
Publicado: (2020)

Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson’s Disease Progression
por: Mollenhauer, Brit, et al.
Publicado: (2020)

Predictors of time to initiation of symptomatic therapy in early Parkinson's disease
por: Simuni, Tanya, et al.
Publicado: (2016)

Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease
por: Kremer, Thomas, et al.
Publicado: (2021)

Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic Development
por: Alcalay, Roy N., et al.
Publicado: (2019)

Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls
por: Mollenhauer, Brit, et al.
Publicado: (2017)

Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease
por: Caspell-Garcia, Chelsea, et al.
Publicado: (2017)

An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson’s Disease and G2019S LRRK2 Cohorts
por: Padmanabhan, Shalini, et al.
Publicado: (2020)

Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease
por: Bartl, Michael, et al.
Publicado: (2021)

The Prejudice towards People with Mental Illness (PPMI) scale: structure and validity
por: Kenny, Amanda, et al.
Publicado: (2018)

Predicting miRNA-disease associations based on PPMI and attention network
por: Xie, Xuping, et al.
Publicado: (2023)

A user's guide for α‐synuclein biomarker studies in biological fluids: Perianalytical considerations
por: Mollenhauer, Brit, et al.
Publicado: (2017)

Deep Learning for Daily Monitoring of Parkinson’s Disease Outside the Clinic Using Wearable Sensors
por: Atri, Roozbeh, et al.
Publicado: (2022)

Central and peripheral α‐synuclein in Parkinson disease detected by seed amplification assay
por: Chahine, Lana M., et al.
Publicado: (2023)

Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial
por: Simuni, Tanya, et al.
Publicado: (2020)

Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson’s Disease
por: Picillo, Marina, et al.
Publicado: (2022)

Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
por: Eusebi, Paolo, et al.
Publicado: (2018)

Extrastriatal (123)I-FP-CIT SPECT impairment in Parkinson’s disease – the PPMI cohort
por: Nicastro, Nicolas, et al.
Publicado: (2020)

Glucosylceramide in cerebrospinal fluid of patients with GBA-associated and idiopathic Parkinson’s disease enrolled in PPMI
por: Huh, Young Eun, et al.
Publicado: (2021)

Beta amyloid deposition and cognitive decline in Parkinson’s disease: a study of the PPMI cohort
por: Mihaescu, Alexander S., et al.
Publicado: (2022)

Rare variants in LRRK1 and Parkinson's disease
por: Schulte, Eva C., et al.
Publicado: (2013)

MAO-B Polymorphism Associated with Progression in a Chinese Parkinson's Disease Cohort but Not in the PPMI Cohort
por: Cui, Shi-Shuang, et al.
Publicado: (2022)

Motor subtypes and clinical characteristics in sporadic and genetic Parkinson's disease groups: analysis of the PPMI cohort
por: Jeong, Eun Hye, et al.
Publicado: (2023)

LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson’s disease patients
por: Ysselstein, Daniel, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2miiop0cirekp6lv3tid4lu6or